13日，由厦门特宝生物工程股份有限公司历时14年研发的生物制品1类新药——派格宾，获得国家食品药品监督管理总局批准正式投产，11月下旬开始进入全国各大医疗机构及定点药店销售。派格宾（聚乙二醇干扰素α-2b注射液），通称长效干扰素，具有抗病毒和免疫调节的双重作用，是慢性丙型肝炎和慢性乙型肝炎的重要治疗药物。这是我国首个拥有全球自主知识产权的国产长效干扰素，也是我省近10年来第一个上市的国家1类新药，已获得30多个国家专利授权。目前，国内长效干扰素市场被国外品牌垄断，价格也不菲。派格宾的上市，将打破国外同类产品在国内的长期垄断，促进同类产品的竞争，迫使进口同类产品
Read More
On October 19, Hu Zucai, counselor of the State Council and former deputy director of the National Development and Reform Commission, accompanied by leaders of the governments of Fujian Province, Xiamen City and Haicang District, visited Tebao Biotech for investigation. Sun Li, chairman and general manager of Tebao Biotech, received the visiting leaders and gave a detailed report on the company's production, operation and development plans, and focused on the role of Pegbin (long-acting interferon) in improving the clinical cure rate of hepatitis B and reducing the risk of liver cancer. research progress in this regard.
Read More
On May 29, Amoytop Biotech's independently developed Class 1 new drug, Inpegsomatropin Injection(trade name: Pegpesen®), the world's first Y-shaped 40-kDa PEGylated long-acting growth hormone, officially received market approval from the National Medical Products Administration (NMPA). This drug is
Read More Jul 22, 2024Xiamen, China, July 22, 2024/--Xiamen Amoytop Biotech Co., Ltd. (referred to as Amoytop hereinafter) today announced that it has entered into a clinical trial collaboration agreement with Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”).
Read More